TICKERNERD
Menu
GMEDGMEDHealthcare · Medical Devices

GMED Stock Forecast: Globus Medical, Inc. Price Predictions for 2026-2027

Last close, 18 Sept 2026
$74
−0.11% on the day

The 15 Wall Street analysts covering Globus Medical, Inc. hold a median 12-month price target of $100 — +35.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 96 of 100 as at 19 Sept 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$9.9B
Ticker Nerd rank
96 / 100
Median analyst target
$100
Analysts covering
15
Revenue$789.6M+5.9% y/y
Operating income$195.5M
Net income$151.6M
Free cash flow$176.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−0.1%
1M
−14.3%
YTD
−15.2%
1Y
+30.5%
From 52W high
−23.5%
From 52W low
+34.4%
$55
$97
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

GMED stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Globus Medical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 19 Sept 2026
96 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
96
Value
96
Revisions
93
Volatility
80
Growth
74
Momentum
68
Issuance
66
Accruals
56
Size
15

Quality (96): The business earns solid, repeatable profits on what it owns.

Accruals (56): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Size (15): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

GMED stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on GMED, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$60$80$100$120Oct 25Jan 26Apr 26Jul 26GMEDHigh $125Median $100Low $84

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says15 analysts
10 Buy5 Hold0 Sell
Low $84Median $100High $125

The green dot is the last close — the median target sits +35.0% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 0 moved their price target up and 4 moved it down.

DateFirmActionRatingTarget
7 Aug 2026Wells FargoMaintainsOverweight$103 → $99
28 July 2026UBSInitiatesNeutral—
28 July 2026UBSInitiatesNeutral$82
16 July 2026Truist SecuritiesMaintainsBuy$115 → $100
16 July 2026Truist SecuritiesMaintainsBuy—
13 July 2026RBC CapitalMaintainsOutperform$120 → $115
13 July 2026RBC CapitalMaintainsOutperform—
9 July 2026BMO CapitalInitiatesOutperform—
8 July 2026StifelMaintainsHold$95 → $80
8 July 2026StifelMaintainsHold—
15 June 2026Piper SandlerMaintainsOverweight—
8 May 2026NeedhamMaintainsBuy—
8 May 2026RBC CapitalMaintainsOutperform—
8 May 2026Wells FargoMaintainsOverweight—
26 Feb 2026Wells FargoMaintainsOverweight—
25 Feb 2026BarclaysMaintainsOverweight—
25 Feb 2026NeedhamMaintainsBuy—
30 Jan 2026NeedhamUpgradeBuy—
9 Jan 2026Canaccord GenuityMaintainsBuy—
8 Jan 2026Piper SandlerReiteratesOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. GMED appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

GMED vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Sept 2026, Globus Medical, Inc. returned +30.5% against +16.3% for the S&P 500, dividends included.

GMED vs S&P 500, last 12 monthsTotal return, rebased to 100
100120140160180Oct 25Jan 26Apr 26Jul 26GMEDS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

GMED analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+5.4%
Analysts raising
13
Analysts cutting
0
Fundamentals

Globus Medical, Inc. (GMED) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
18.9×

Cheaper than 39% of US stocks

Price / sales
3.2×

Cheaper than 39% of US stocks

Price / book
2.1×

Cheaper than 44% of US stocks

EV / EBITDA
9.4×

Cheaper than 40% of US stocks

Growth & margins
Revenue growth (YoY)
5.9%

Higher than 41% of US stocks

Earnings growth (YoY)
−25.3%

Higher than 18% of US stocks

Gross margin
69.4%

Higher than 82% of US stocks

Operating margin
24.8%

Higher than 84% of US stocks

Net margin
17.0%

Higher than 80% of US stocks

Returns & dividend
Return on equity
11.8%

Higher than 68% of US stocks

Return on assets
8.7%

Higher than 90% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Globus Medical, Inc. (GMED) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Globus Medical, Inc. has a market value of $9.9B and an enterprise value of $9.5B.

  • Revenue in the twelve months to 30 June 2026: $3.1B. The latest quarter grew 5.9% year on year.

  • Net income over the same four quarters: $535.4M, a 17.0% net margin.

  • Diluted earnings per share, trailing twelve months: $3.91.

  • Free cash flow in the twelve months to 30 June 2026: $745.8M.

  • Globus Medical, Inc. spent $221.1M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 134.3M.

  • Trailing P/E: 18.9×; forward P/E: 13.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Globus Medical, Inc. employs 6,000 people — $524K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 19 Sept 2026

Data provided by Twelve Data

Peers

GMED vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
GMEDGlobus Medical, Inc.$9.9B
96
TXG10X Genomics, Inc.$10.0B
94
BIOBio-Rad Laboratories, Inc.$10.1B
90
PODDInsulet Corp.$9.7B
89
GKOSGlaukos Corp.$9.7B
92
BRKRBruker Corp.$9.3B
87
PENPenumbra, Inc.$12.5B
75

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Globus Medical, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest GMED news & analysis

What Makes Globus Medical (GMED) a New Strong Buy Stock

Zacks Investment Research · 16 Sept 2026positive

Zacks Investment Research upgraded Globus Medical (GMED) to a Zacks Rank #1 (Strong Buy), citing growing optimism about its earnings prospects. The upgrade suggests the stock may move higher based on improved expectations.

Why it matters — A Zacks upgrade to Strong Buy signals improved analyst sentiment on GMED's earnings outlook, which watchers may consider a meaningful positive for the stock.

Top Robotics Stocks to Add to Your Portfolio for Impressive Returns

Zacks Investment Research · 15 Sept 2026positive

Zacks Investment Research highlighted robotics stocks poised for robust long-term growth, naming GMED along with NVDA, TER, and ZBRA as companies with potential for market dominance across sectors.

Why it matters — GMED was explicitly identified as a robotics stock positioned for long-term growth and potential market dominance, which may draw attention to the company's robotics-related prospects.

GMED vs. ITGR: Which Stock Should Value Investors Buy Now?

Zacks Investment Research · 14 Sept 2026neutral

Zacks Investment Research published a comparison of Globus Medical (GMED) and Integer (ITGR), two medical instruments stocks, evaluating which one value investors seeking undervalued companies should consider. The article presents a head-to-head valuation analysis of the two companies without issuing a definitive recommendation.

Why it matters — GMED watchers would care because the piece offers a comparative valuation perspective on Globus Medical relative to a peer in the same sector, which can inform how the stock is viewed among value investors.

Why Globus Medical (GMED) is a Top Value Stock for the Long-Term

Zacks Investment Research · 14 Sept 2026positive

Zacks Investment Research highlights Globus Medical (GMED) as a top value stock for the long term. The article references Zacks Style Scores, a feature of the Zacks Premium research service, as a tool to help identify strong stocks across value, growth, and momentum styles.

Why it matters — GMED watchers would care because the stock is being singled out as a strong long-term value pick, offering independent research recognition of its investment merits.

New Strong Buy Stocks for September 11th

Zacks Investment Research · 11 Sept 2026positive

On September 11, 2026, Globus Medical, Inc. (GMED) was added to the Zacks Rank #1 (Strong Buy) List, along with RCMT, HCSG, BLMN, and AGX, according to Zacks Investment Research.

Why it matters — A GMED watcher would care because the stock received a Zacks Strong Buy designation, marking a notable ranking update from an investment research firm.

FAQ

Frequently asked questions about GMED stock

What is the GMED stock price forecast for 2026-2027?

The 15 Wall Street analysts covering Globus Medical, Inc. have a median 12-month price target of $100, with estimates ranging from $84 to $125. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is GMED stock a buy right now?

Of the 15 analysts covering Globus Medical, Inc., 10 rate it a Buy, 5 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Globus Medical, Inc. 96 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank GMED?

As at 19 Sept 2026, Globus Medical, Inc. ranks 96 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (96 of 100).

Will GMED stock go up?

No one can know that. What the data says: the median 12-month target from 15 analysts implies +35.0% from the last close, and Ticker Nerd's factor model ranks Globus Medical, Inc. 96 out of 100 as at 19 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the GMED stock forecast for 2030?

No analyst covering Globus Medical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GMED are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $84 to $125 over the next 12 months.

How has GMED stock performed over the past year?

Globus Medical, Inc. returned +30.5% over the 12 months to 18 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Globus Medical, Inc. do?

Globus Medical Inc. Class A Common Stock represents ownership in Globus Medical, a medical device company focused on musculoskeletal care.

What is the latest news on GMED?

The most recent item we track (Zacks Investment Research, 16 Sept 2026): "What Makes Globus Medical (GMED) a New Strong Buy Stock". Zacks Investment Research upgraded Globus Medical (GMED) to a Zacks Rank #1 (Strong Buy), citing growing optimism about its earnings prospects. The upgrade suggests the stock may move higher based on improved expectations.

Company

About Globus Medical, Inc.

Globus Medical Inc. Class A Common Stock represents ownership in Globus Medical, a medical device company focused on musculoskeletal care. The company develops and commercializes products for spine and orthopaedic applications, including implant systems, surgical instruments, and enabling technologies used in hospitals, physician practices, and surgical centers. Its portfolio supports procedures for spinal disorders, bone healing, and other complex musculoskeletal conditions, making it a significant supplier in the healthcare equipment market. Globus Medical also provides integrated solutions that combine devices, instrumentation, and technology to support surgical workflows and patient treatment. Headquartered in Audubon, Pennsylvania, Globus Medical serves healthcare providers in the United States and internationally.

CEO Mr. Keith W. Pfeil · 6,000 employees · United States · https://www.globusmedical.com